Cytiva—which employs more than 7,000 people worldwide—will carry out its expansion across its global product manufacturing and distribution network, which encompasses 13 sites across the U.S. and the rest of the Americas, as well as Asia and Europe.
Researchers at the University of Washington School of Medicine Institute for Protein Design used computers to design small proteins that bind tightly to the SARS-CoV-2 Spike protein and prevent it from infecting human cells. The lead antiviral candidate, LCB1, appears to rival the most effective known SARS-CoV-2 neutralizing antibodies in protecting against the virus, and is currently undergoing evaluation in rodents.
Each year fungal diseases affect billions of people globally, causing an estimated 1.6 million deaths. Infections resistant to treatment are a growing problem, particularly in patients with weakened immune systems, such as those with HIV. Since few effective antifungal drugs exist, it is imperative to understand the nature of fungal resistance and how it develops. Thankfully, investigators at the University of Edinburgh have just made a discovery that could be the key to how resistance mechanisms grow over time.
A study from Arizona State University (ASU) and the European X-ray Free Electron Laser (EuXFEL) reportedly validated a microfluidic droplet generator for reducing sample size as well as waste (which can be as high as 99%) in ASU’s Serial Femtosecond Crystallography (SFX) experiments. Their results advocate for future routine integration of droplet generation by segmented oil flow at other XFELs around the world.
Sponsor: TecanJoin us for Episode 4 of GEN Live, sponsored by Tecan. In this live zoom event we discuss the state of vaccine development for COVID-19. We evaluate the front-runners, explore the potential of RNA vaccines, ponder the challenges of manufacturing, and tackle questions about herd immunity.
Completion of its HPAPI and ADC facility project is expected by mid-2022.
Don’t erase markers of aging when you model cardiovascular tissue. Preserve them. That is, if you use direct conversion when reprogramming adult fibroblasts, you can skip the erasures that would occur if you were to take the cells through induced pluripotency. Direct conversion has already been used to identify molecular targets for drug discovery.
The CEOs' statement comes as their companies scramble to maintain momentum as leaders in the race to bring their COVID-19 vaccines through approvals to patients worldwide—and as President Donald Trump said Friday that the U.S. “remains on track to deliver a vaccine before the end of the year and maybe even before November 1st” based on "shockingly good results" to date in clinical trials.
The largest study to date to analyze the breast milk microbiota in mothers of preterm infants highlights the individual complexity of the preterm mother’s milk microbiota. In addition, the findings suggest that even short courses of antibiotics have prolonged effects on the diversity and abundance of microbes in their milk.
Sanofi and GSK anticipate first results in early December 2020, when the companies expect to launch a Phase III trial. Should the data prove positive, Sanofi and GSK said, they plan to request regulatory approval for their vaccine in the first half of 2021.